%0 Case Reports
%T Commercialized Hybrid Closed-Loop System (Minimed Medtronic 670G) Results During Pregnancy.
%A Moreno-Fernández J
%A García-Seco JA
%J AACE Clin Case Rep
%V 7
%N 3
%D May-Jun 2021
%M 34095482
暂无%R 10.1016/j.aace.2020.11.039
%X <B>UNASSIGNED: </B>Hybrid closed-loop (HCL) devices can achieve tight glycemic control but are rarely used in pregnancy, which remains an off-label indication. We present a case of a pregnant patient with type 1 diabetes mellitus (T1DM) who used the Medtronic MiniMed 670G HCL system.<BR><B>UNASSIGNED: </B>MiniMed 670G includes an advanced automode option (HCL therapy), which our patient used from the first trimester to the end of the pregnancy.<BR><B>UNASSIGNED: </B>An unplanned pregnancy was detected in the T1DM patient, with a glycated hemoglobin level of 8.7 mmol/L (7.1%). The patient started sensor-augmented pump therapy at week 13. Subsequently, she entered automode (HCL) at week 16. The time in range (3.7-7.8 mmol/mol, 63-140 mg/dL) increased from 46.8% to 51.3% after HCL initiation. The glycated hemoglobin level remained close to 48 mmol/mol (6.5%) until the end of the pregnancy. Furthermore, the time under range (<3.7 mmol/mol, <63 mg/dL) remained below the optimal 4% level during the gestation. Finally, a healthy male baby was born at week 37. No safety events were recorded.<BR><B>UNASSIGNED: </B>This case represents the successful off-label use of HCL during pregnancy in a patient with T1DM.